Researchers dig into data to predict kidney decline in ADPKD patients on octreotide
NCT ID NCT06193616
First seen Oct 31, 2025 · Last updated May 13, 2026 · Updated 26 times
Summary
This study looks back at medical records from 70 adults with advanced polycystic kidney disease (ADPKD) who are taking the drug octreotide LAR. The goal is to see if baseline factors like total kidney volume can predict how quickly their kidney function declines over time. No new treatments are being tested; instead, researchers hope to better understand the disease and improve future care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ASST HPG23 - Unità di Nefrologia
Bergamo, BG, 24100, Italy
Conditions
Explore the condition pages connected to this study.